Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

At the end of the day, GLP-1s can be a powerful tool for achieving your weight loss goals, but only if they're safe and ...

The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity ...

Country is facing epidemic of diabetes and obesity, but experts say widespread and unregulated use of weight loss drugs could put patients at risk ...

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

Below is a comparison of today’s most prescribed GLP-1 medications, including Ozempic and Trulicity, both widely used for ...

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...

India’s medical community has raised the alarm over the rapid and uncontrolled increase in the use of weight-loss injections, ...

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

Leading Indian doctors caution against the unregulated increase in weight loss injections, highlighting their misuse and potential long-term health risks.

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue ...